1. Home
  2. ALT vs DIAX Comparison

ALT vs DIAX Comparison

Compare ALT & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • DIAX
  • Stock Information
  • Founded
  • ALT 1997
  • DIAX 2005
  • Country
  • ALT United States
  • DIAX United States
  • Employees
  • ALT N/A
  • DIAX N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • DIAX Finance Companies
  • Sector
  • ALT Health Care
  • DIAX Finance
  • Exchange
  • ALT Nasdaq
  • DIAX Nasdaq
  • Market Cap
  • ALT 472.3M
  • DIAX 477.5M
  • IPO Year
  • ALT N/A
  • DIAX N/A
  • Fundamental
  • Price
  • ALT $5.59
  • DIAX $14.01
  • Analyst Decision
  • ALT Strong Buy
  • DIAX
  • Analyst Count
  • ALT 7
  • DIAX 0
  • Target Price
  • ALT $21.00
  • DIAX N/A
  • AVG Volume (30 Days)
  • ALT 2.0M
  • DIAX 96.6K
  • Earning Date
  • ALT 05-13-2025
  • DIAX 01-01-0001
  • Dividend Yield
  • ALT N/A
  • DIAX 7.93%
  • EPS Growth
  • ALT N/A
  • DIAX N/A
  • EPS
  • ALT N/A
  • DIAX N/A
  • Revenue
  • ALT $20,000.00
  • DIAX N/A
  • Revenue This Year
  • ALT N/A
  • DIAX N/A
  • Revenue Next Year
  • ALT N/A
  • DIAX N/A
  • P/E Ratio
  • ALT N/A
  • DIAX N/A
  • Revenue Growth
  • ALT N/A
  • DIAX N/A
  • 52 Week Low
  • ALT $3.55
  • DIAX $12.80
  • 52 Week High
  • ALT $11.16
  • DIAX $15.12
  • Technical
  • Relative Strength Index (RSI)
  • ALT 56.67
  • DIAX 52.21
  • Support Level
  • ALT $4.95
  • DIAX $13.88
  • Resistance Level
  • ALT $6.05
  • DIAX $14.17
  • Average True Range (ATR)
  • ALT 0.37
  • DIAX 0.16
  • MACD
  • ALT 0.10
  • DIAX 0.07
  • Stochastic Oscillator
  • ALT 65.67
  • DIAX 83.33

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.

Share on Social Networks: